Companies → Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Save to list
Remove

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

China, Guangdong, Shenzhen
Description
How's this for international: Mindray Medical International is a Cayman Islands holding company, publicly traded in the US, and doing business in China primarily through operating subsidiary Shenzhen Mindray. As for the medical part of the business, Mindray Medical International develops, manufactures, and markets a range of medical devices, including patient monitoring and life support devices, medical imaging systems, and in-vitro diagnostic instruments. With a direct sales force and a distributor network in China, the US, and Europe, its products are sold in more than 160 countries worldwide. Customers include hospitals, clinics, government health bureaus, and original equipment manufacturers.
Address:

Floor 1-4

Mindray Building

Keji South 12th Road

High-tech Industrial Park

Nanshan District Shenzhen

Guangdong

518063 China

Website:
Revenue
Recent news:

How Medtronic’s Ambulatory Surgery Center Push With Mindray (MDT) Has Changed Its Investment Story

Medtronic recently extended its partnership with Mindray to integrate Microstream capnography and Nellcor pulse oximetry into Mindray’s patient monitoring platforms for ambulatory surgery centers, while also enhancing clinical training, post-sales support, and purchasing processes. This deeper collaboration highlights Medtronic’s effort to embed its monitoring technologies more firmly in the fast-growing ambulatory surgery center market and expand its footprint in medical-grade wearables...

Source: Simply Wall St. Jan 31, 2026

Medtronic Targets Atrial Fibrillation Growth And ASC Demand With New Moves

Medtronic (NYSE:MDT) received a CE mark for its Affera Sphere-360 pulsed field ablation catheter, opening access to European atrial fibrillation treatment markets. The company also extended its partnership with Mindray to further integrate patient monitoring technology in ambulatory surgery centers. For Medtronic, a large medical technology company focused on cardiovascular and other chronic disease treatments, these moves target two active parts of healthcare: atrial fibrillation...

Source: Simply Wall St. Jan 30, 2026

Medtronic Cardiac Tech And Mindray Partnership Underpin Neutral Valuation Story

Medtronic (NYSE:MDT) received CE Mark approval in Europe for its Affera Sphere-360 pulsed field ablation catheter for cardiac ablation procedures. The company has started pivotal U.S. clinical trials for the Affera Sphere-360 system, including first-in-human procedures. Medtronic extended its partnership with Mindray to integrate Medtronic patient monitoring technology into ambulatory surgery centers. For investors watching Medtronic at a share price of $100.69, these product and...

Source: Simply Wall St. Jan 28, 2026

Medtronic targets ASCs with extended Mindray collaboration

Mindray is integrating Medtronic patient monitoring technologies into its platforms to meet the needs of ambulatory surgery centers.

Source: MedTech Dive Jan 27, 2026

Mindray Bio-Medical Files for $1B+ Hong Kong Listing

China's leading medical device firm Mindray files for Hong Kong listing to raise over $1 billion for global R&D and digital healthcare expansion.

Source: IndexBox Nov 11, 2025

Medical device stocks slide on Trump tariff news

Medical devices, or the medtech sector, are not immune from the reciprocal tariffs announced by Trump yesterday.

Source: Yahoo Finance Apr 3, 2025

SZSE - Delayed Quote - CNY
300760.SZ
Candle
Line
1M
6M
1Y
5Y
Financial Statistics
Valuation Measures
Current
Quarterly
As of 03/20/2026
Market Cap: 205.53 B
Enterprise Value: 188.38 B
Trailing P/E: 23.87
Forward P/E: 17.18
PEG Ratio (5yr expected): 6.36
Price/Sales (ttm): 6.21
Price/Book (mrq): 5.23
Enterprise Value/Revenue: 5.70
Enterprise Value/EBITDA: 19.08
Financial Highlights
Profitability and Income Statement
Profit Margin: 26.01%
Return on Assets (ttm): 9.88%
Return on Equity (ttm): 20.52%
Revenue (ttm): 33.07 B
Net Income Avi to Common (ttm): 8.60 B
Diluted EPS (ttm): 7.10
Balance Sheet and Cash Flow
Total Cash (mrq): 17.52 B
Total Debt/Equity (mrq): 0.81%
Levered Free Cash Flow (ttm): 3.74 B
Company is likely to sell
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.